Wave Life Sciences Ltd
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNumber | Exhibit Description | Filedwith thisReport | Incorporated byReference hereinfrom Form orSchedule | FilingDate | SECFile/Reg.Number |
|---|---|---|---|---|---|
| 4.1 | Form of Pre-Funded Warrant | Form 8-K(Exhibit 4.1) | 9/26/2024 | 001-37627 | |
| 10.1 | Amendment No. 3, dated November 12, 2024, to the Open Market Sale Agreement, dated as of May 10, 2019, by and between Wave Life Sciences Ltd. and Jefferies LLC | X | |||
| 10.2+ | Non-Employee Director Compensation Policy, effective as of August 6, 2024 | X | |||
| 10.3+ | Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended | Form 8-K (Exhibit 10.1) | 8/12/2024 | 001-37627 | |
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer | X | |||
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer | X | |||
| 32* | Section 1350 Certifications of Principal Executive Officer and Principal Financial Officer | X | |||
| 101.INS | Inline XBRL Instance Document – The instance document does not appear in the interactive data file because its Inline XBRL tags are embedded within the Inline XBRL document | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | |||
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) | X | |||
(*) The certifications attached as Exhibit 32 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Wave Life Sciences Ltd. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.
(+) Indicates management contract or compensatory plan or arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| WAVE LIFE SCIENCES LTD. | ||
| Date: November 12, 2024 | By: | /s/ Paul B. Bolno, M.D., MBA |
|---|---|---|
| Paul B. Bolno, M.D., MBA | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Date: November 12, 2024 | By: | /s/ Kyle Moran |
| Kyle Moran | ||
| Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.